Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis

Matsuda, Kenji; Hotta, Tsukasa; Takifuji, Katsunari; Yamamoto, Manabu; Nasu, Toru; Togo, Naoki; Oka, M.; Tabuse, Katsuyoshi; Yamaue, Hiroki

doi:10.1016/j.surg.2010.10.018

Cited by 23 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cytoreduction should be planned according to the area at risk of incomplete resection 60 . The area of the abdomen at highest risk of incomplete resection should be addressed first, because it serves as an indicator-that is, the procedure should be stopped if the resection is not possible 28,61,62 (loc b).…”

Section: Crsmentioning

confidence: 99%

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

et al. 2015

View full text Add to dashboard Cite

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

show abstract

Section: Crsmentioning

confidence: 99%

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This trial has just closed for inclusion and final results on overall survival should be available in 2017. Two retrospective [37,38] and one prospective [39] studies have reported survivals of patients who had a complete resection of the PM without intraperitoneal treatment; the 5-year overall survival ranged from 24 to 36 %, but their non-randomized manner and their small effective make conclusions difficult to do.…”

Section: Evidence For Crs and Hipec For Pm From Colorectal Cancermentioning

confidence: 99%

“…Mitomycin has been used due to its high molecular weight, tissue penetration up to 5 mm and a favorable pharmacokinetic profile that permits increased intraperitoneal concentration with limited systemic toxicity [55]. Elias et al have shown the efficacy and safety of intraperitoneal oxaliplatin in pharmacological and clinical studies both [38]. Though the PRODIGE-7 trial will answer the question about the benefit of HIPEC in addition to CRS, it will not answer the question regarding which technique or drug is superior, as both a the techniques could be performed according to the choice of the surgeon.…”

Section: Hipec Methologymentioning

confidence: 99%

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Bhatt

Goèré

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Occurring either synchronously or metachronously to the primary tumor, peritoneal metastases (PM) are diagnosed in 8 to 20 % of the patients with colorectal cancer (CRC). Prognosis of these patients appears to be worse than those with other sites of metastases. While systemic therapy has shown significant prolongation of survival in patients with stage IV colorectal cancer, the outcomes in the subset of patients with PM has been much inferior. Over the last 2 decades, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been effective in substantially prolonging survival in patients with colorectal PM and have the potential to cure certain patients as well. This article reviews the current evidence for CRS and HIPEC to treat colorectal PM as well as future research going on in this form of locoregional treatment.

show abstract

“…The subsequent search strategy identified 259 new articles to add to the 6522 articles initially analysed. The majority of the studies were excluded and seven studies were eventually considered informative concerning the risk for developing PM and added to the 16 studies reported in the previous review [12,[14][15][16][17][18][19][20]. All 23 studies were non-randomised.…”

Section: Resultsmentioning

confidence: 99%

Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?

Honoré

Gelli

Francoual

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis

Cited by 23 publications

References 15 publications

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?

Contact Info

Product

Resources

About